249 related articles for article (PubMed ID: 15288283)
1. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Eggermont AM; Kirkwood JM
Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
[TBL] [Abstract][Full Text] [Related]
2. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
4. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
[TBL] [Abstract][Full Text] [Related]
7. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
[TBL] [Abstract][Full Text] [Related]
8. Management of metastatic melanoma.
Tawbi HA; Kirkwood JM
Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
10. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
Jansen B; Wacheck V; Heere-Ress E; Schlagbauer-Wadl H; Hoeller C; Lucas T; Hoermann M; Hollenstein U; Wolff K; Pehamberger H
Lancet; 2000 Nov; 356(9243):1728-33. PubMed ID: 11095261
[TBL] [Abstract][Full Text] [Related]
13. Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.
Hochster H; Levin M; Speyer J; Dunleavy S; Harris M; Roses D; Golomb F; Muggia F
Cancer Treat Rep; 1985 Jan; 69(1):39-42. PubMed ID: 3967259
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy.
Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
[TBL] [Abstract][Full Text] [Related]
15. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
16. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
17. Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature.
Mohammadianpanah M; Shirazi M; Mosalaei A; Omidvari S; Ahmadloo N
Clin Ther; 2007 Jun; 29(6):1161-5. PubMed ID: 17692730
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
19. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
20. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]